BLACK DIAMOND THERAPEUTICS I (BDTX) Stock Price & Overview
NASDAQ:BDTX • US09203E1055
Current stock price
The current stock price of BDTX is 2.11 USD. Today BDTX is down by -1.86%. In the past month the price decreased by -9.44%. In the past year, price increased by 18.54%.
BDTX Key Statistics
- Market Cap
- 120.207M
- P/E
- 5.55
- Fwd P/E
- N/A
- EPS (TTM)
- 0.38
- Dividend Yield
- N/A
BDTX Stock Performance
BDTX Stock Chart
BDTX Technical Analysis
ChartMill assigns a technical rating of 1 / 10 to BDTX. When comparing the yearly performance of all stocks, BDTX turns out to be only a medium performer in the overall market: it outperformed 51.88% of all stocks.
BDTX Fundamental Analysis
ChartMill assigns a fundamental rating of 4 / 10 to BDTX. While BDTX has a great health rating, its profitability is only average at the moment.
BDTX Earnings
BDTX Forecast & Estimates
15 analysts have analysed BDTX and the average price target is 9.31 USD. This implies a price increase of 341.11% is expected in the next year compared to the current price of 2.11.
For the next year, analysts expect an EPS growth of -234.45% and a revenue growth -100% for BDTX
BDTX Groups
Sector & Classification
BDTX Financial Highlights
Over the last trailing twelve months BDTX reported a non-GAAP Earnings per Share(EPS) of 0.38. The EPS increased by 129.91% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 31.95% | ||
| ROA | 15.64% | ||
| ROE | 19.93% | ||
| Debt/Equity | 0 |
BDTX Ownership
BDTX Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 13.82 | 362.599B | ||
| AMGN | AMGEN INC | 15.24 | 187.489B | ||
| GILD | GILEAD SCIENCES INC | 15.52 | 170.335B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 23.42 | 115.33B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.68 | 77.479B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 41.84 | 41.4B | ||
| INSM | INSMED INC | N/A | 29.315B | ||
| NTRA | NATERA INC | N/A | 27.677B | ||
| BIIB | BIOGEN INC | 11.29 | 26.631B | ||
| UTHR | UNITED THERAPEUTICS CORP | 17.55 | 22.979B | ||
| MRNA | MODERNA INC | N/A | 20.292B | ||
| EXAS | EXACT SCIENCES CORP | 345.14 | 20.026B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 18.981B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About BDTX
Company Profile
Black Diamond Therapeutics, Inc. is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. The company is headquartered in Cambridge, Massachusetts and currently employs 21 full-time employees. The company went IPO on 2020-01-30. The Company’s MasterKey therapies are designed to address a broad spectrum of genetically defined tumors, overcome resistance, minimize wild-type mediated toxicities, and be brain penetrant to treat central nervous system disease. The firm is advancing a Phase 2 NSCLC trial of BDTX-1535, a brain-penetrant fourth-generation epidermal growth factor receptor (EGFR) MasterKey inhibitor targeting EGFR-mutant NSCLC and glioblastoma. Its BDTX-4933 pipeline product is out-licensed to Servier. BDTX-4933 is designed to target RAS and RAF alterations in solid tumors. The company is exploring partnership opportunities for its FGFR2/3 selective development candidate BDTX-4876.
Company Info
IPO: 2020-01-30
BLACK DIAMOND THERAPEUTICS I
245 First Street, 18Th Floor
Cambridge MASSACHUSETTS 02142 US
CEO: David M. Epstein
Employees: 21
Phone: 16174175868
BLACK DIAMOND THERAPEUTICS I / BDTX FAQ
Can you describe the business of BLACK DIAMOND THERAPEUTICS I?
Black Diamond Therapeutics, Inc. is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. The company is headquartered in Cambridge, Massachusetts and currently employs 21 full-time employees. The company went IPO on 2020-01-30. The Company’s MasterKey therapies are designed to address a broad spectrum of genetically defined tumors, overcome resistance, minimize wild-type mediated toxicities, and be brain penetrant to treat central nervous system disease. The firm is advancing a Phase 2 NSCLC trial of BDTX-1535, a brain-penetrant fourth-generation epidermal growth factor receptor (EGFR) MasterKey inhibitor targeting EGFR-mutant NSCLC and glioblastoma. Its BDTX-4933 pipeline product is out-licensed to Servier. BDTX-4933 is designed to target RAS and RAF alterations in solid tumors. The company is exploring partnership opportunities for its FGFR2/3 selective development candidate BDTX-4876.
What is the current price of BDTX stock?
The current stock price of BDTX is 2.11 USD. The price decreased by -1.86% in the last trading session.
Does BLACK DIAMOND THERAPEUTICS I pay dividends?
BDTX does not pay a dividend.
How is the ChartMill rating for BLACK DIAMOND THERAPEUTICS I?
BDTX has a ChartMill Technical rating of 1 out of 10 and a ChartMill Fundamental rating of 4 out of 10.
Where is BLACK DIAMOND THERAPEUTICS I (BDTX) stock traded?
BDTX stock is listed on the Nasdaq exchange.
What do analysts say about BLACK DIAMOND THERAPEUTICS I (BDTX) stock?
15 analysts have analysed BDTX and the average price target is 9.31 USD. This implies a price increase of 341.11% is expected in the next year compared to the current price of 2.11.
Can you provide the growth outlook for BLACK DIAMOND THERAPEUTICS I?
The Revenue of BLACK DIAMOND THERAPEUTICS I (BDTX) is expected to decline by -100% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.